July 12, 2023
2 minutes watch
Source/disclosure information
Issuer:
sauce: Helio interview
Disclosure:
Loftus Reports Consulting Research support from AbbVie, Albotech, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion Healthcare, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Takeda Pharmaceuticals; AbbVie, Bristol-Myers Squibb, Celgene /Research support from Receptos, Gilead, Janssen, and Takeda.
In the Helio exclusive video, Edward V. Loftus, Jr., MDacknowledged that while artificial intelligence has the potential to fundamentally change the way gastroenterologists practice, “it won’t replace you.”
In the June issue, helio gastroenterology‘s cover story leverages text, images, and other data to recreate the medical opinion of an expert, focusing on technology with the added benefits of standardization, reproducibility, and speed, highlighting the rapid rise of AI in healthcare. I am thinking about the rise of The clinical benefits are clear in medical specialties such as gastroenterology and hepatology, which rely on extensive imaging studies for early detection and tailoring of patient treatment.
“As you know, for better or for worse, AI is a hot topic these days,” Loftus, the Mayo Clinic’s Maxine and Jack Zarrow family gastroenterology professor, told Helio. . “In this article, we interview a number of experts on various aspects of AI in IBD. How can endoscopic grading be enhanced?”
But despite its enormous benefits, AI is just a tool, and real implementation of the technology will require doctors to stay up-to-date to provide feedback, Loftus said. warned.
“The key message is that AI is very promising, but it’s not ready for prime time yet,” he said. “If AI is used in clinical practice, it should be used under close supervision. It will not replace you and may enhance your ability to do your job, but again but it requires great attention to detail and oversight to ensure it is properly implemented.”
AI Resource Center in Medicine
